SciSparc Ltd. (SPRC)
- Previous Close
1.2500 - Open
1.2700 - Bid 1.2400 x 400
- Ask 1.2700 x 400
- Day's Range
1.2400 - 1.2900 - 52 Week Range
1.1500 - 23.6600 - Volume
27,524 - Avg. Volume
850,736 - Market Cap (intraday)
3.872M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-326.4000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
scisparc.comRecent News: SPRC
Performance Overview: SPRC
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRC
Valuation Measures
Market Cap
3.87M
Enterprise Value
-1.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.01
Price/Book (mrq)
0.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-177.91%
Return on Assets (ttm)
-33.12%
Return on Equity (ttm)
-73.37%
Revenue (ttm)
2.88M
Net Income Avi to Common (ttm)
-5.12M
Diluted EPS (ttm)
-326.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.08M
Total Debt/Equity (mrq)
0.79%
Levered Free Cash Flow (ttm)
-5.92M
Research Analysis: SPRC
Company Insights: SPRC
SPRC does not have Company Insights